Secondary Logo

Institutional members access full text with Ovid®

Brexanolone Injection in Postpartum Depression

Two Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trials

Meltzer-Brody, Samantha; Colquhoun, Helen; Riesenberg, Robert; Epperson, C. Neill; Deligiannidis, Kristina M.; Rubinow, David R.; Li, Haihong; Sankoh, Abdul J.; Clemson, Christine; Schacterle, Amy; Jonas, Jeffrey; Kanes, Stephen

Obstetrical & Gynecological Survey: April 2019 - Volume 74 - Issue 4 - p 219–220
doi: 10.1097/01.ogx.0000554376.54568.64
GYNECOLOGY: ENDOCRINOLOGY OF PREGNANCY
Buy

(Abstracted from Lancet 2018;392:1058–1070)

Postpartum depression effects 10% to 20% of women who give birth worldwide, and approximately 40% to 80% of cases are considered moderate to severe. The burden of this disorder is multifactorial, with financial, social, and health-related consequences for mothers and families.

Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC (S.M.-B., D.R.R.); Sage Therapeutics, Cambridge, MA (H.C., H.L., A.J.S., C.C., A.S., J.J., S.K.); Atlanta Center for Medical Research, Atlanta, GA (R.R.); Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (C.N.E.); Feinstein Institute for Medical Research, Northwell Health, Manhasset (K.M.D.); and Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks (K.M.D.), NY

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.